NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.24 -0.13 (-0.85 %) (As of 05/29/2020 10:02 AM ET) Add Compare Share Today's Range$15.06Now: $15.24▼$15.4050-Day Range$14.50MA: $16.34▼$18.3352-Week Range$3.52Now: $15.24▼$21.93Volume88,097 shsAverage Volume1.20 million shsMarket Capitalization$1.71 billionP/E RatioN/ADividend YieldN/ABeta1.41 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.29, Aurinia Pharmaceuticals has a potential upside of 59.4% from its current price of $15.24.Amount of Analyst CoverageAurinia Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesAurinia Pharmaceuticals has received 516 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAurinia Pharmaceuticals has received 333 “underperform” votes. (Add your “underperform” vote.)Community SentimentAurinia Pharmaceuticals has received 60.78% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote “Outperform” if you believe AUPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Institutions52.97% of the stock of Aurinia Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.96) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -11.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -11.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 6.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUPH Previous Symbol CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Debt Debt-to-Equity Ratio0.02 Current Ratio21.01 Quick Ratio21.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$320,000.00 Price / Sales5,348.29 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book6.49Profitability EPS (Most Recent Fiscal Year)($0.89) Net Income$-123,850,000.00 Net Margins-43,965.98% Return on Equity-40.66% Return on Assets-33.89%Miscellaneous Employees39 Outstanding Shares112,300,000Market Cap$1.71 billion Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:AUPH Rates by TradingView Receive AUPH News and Ratings via Email Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions How has Aurinia Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AUPH shares have increased by 8.1% and is now trading at $15.24. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals. When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aurinia Pharmaceuticals. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its earnings results on Thursday, May, 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.05. The biotechnology company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 43,965.98% and a negative return on equity of 40.66%. View Aurinia Pharmaceuticals' earnings history. What price target have analysts set for AUPH? 8 Wall Street analysts have issued 12-month price targets for Aurinia Pharmaceuticals' stock. Their forecasts range from $14.00 to $32.00. On average, they anticipate Aurinia Pharmaceuticals' share price to reach $24.29 in the next year. This suggests a possible upside of 59.4% from the stock's current price. View analysts' price targets for Aurinia Pharmaceuticals. Has Aurinia Pharmaceuticals been receiving favorable news coverage? Media headlines about AUPH stock have trended extremely negative on Friday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of -4.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAurinia Pharmaceuticals. Are investors shorting Aurinia Pharmaceuticals? Aurinia Pharmaceuticals saw a decline in short interest in April. As of April 30th, there was short interest totaling 4,740,000 shares, a decline of 5.0% from the April 15th total of 4,990,000 shares. Based on an average daily trading volume, of 1,540,000 shares, the days-to-cover ratio is currently 3.1 days. Currently, 5.5% of the shares of the stock are sold short. View Aurinia Pharmaceuticals' Current Options Chain. Who are some of Aurinia Pharmaceuticals' key competitors? Some companies that are related to Aurinia Pharmaceuticals include Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), Nektar Therapeutics (NKTR) and Zai Lab (ZLAB). View all competitors. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Cara Therapeutics (CARA), Array Biopharma (ARRY), Alibaba Group (BABA), Exelixis (EXEL), Novavax (NVAX) and Corbus Pharmaceuticals (CRBP). Who are Aurinia Pharmaceuticals' key executives? Aurinia Pharmaceuticals' management team includes the following people: Mr. Michael R. Martin, Co-Founder & COOMr. Dennis Bourgeault CPA, C.A., CFO & Sec.Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.Dr. Richard M. Glickman, Advisor (Age 61)Dr. Neil Solomons M.D., Chief Medical Officer What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH." Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Pictet Asset Management Ltd. (1.44%), Orbimed Advisors LLC (1.19%), Franklin Resources Inc. (1.12%), Connor Clark & Lunn Investment Management Ltd. (0.96%), Assenagon Asset Management S.A. (0.89%) and BlackRock Inc. (0.83%). Which major investors are selling Aurinia Pharmaceuticals stock? AUPH stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Ghost Tree Capital LLC, Creative Planning, Morgan Stanley, Victory Capital Management Inc., Victory Capital Management Inc., Franklin Resources Inc., and Toronto Dominion Bank. Which major investors are buying Aurinia Pharmaceuticals stock? AUPH stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A., Vivo Capital LLC, Wells Fargo & Company MN, Lord Abbett & CO. LLC, Atom Investors LP, and Two Sigma Advisers LP. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aurinia Pharmaceuticals' stock price today? One share of AUPH stock can currently be purchased for approximately $15.24. How big of a company is Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has a market capitalization of $1.71 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe. What is Aurinia Pharmaceuticals' official website? The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
